- Home
- RCEL vs CNTX Comparison
RCEL vs CNTX Comparison
Compare RCEL & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- CNTX
- Stock Information
- Founded
- RCEL N/A
- CNTX 2015
- Country
- RCEL United States
- CNTX United States
- Employees
- RCEL N/A
- CNTX N/A
- Industry
- RCEL Medical/Dental Instruments
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- CNTX Health Care
- Exchange
- RCEL Nasdaq
- CNTX Nasdaq
- Market Cap
- RCEL 114.3M
- CNTX 102.9M
- IPO Year
- RCEL N/A
- CNTX 2021
- Fundamental
- Price
- RCEL $3.91
- CNTX $1.13
- Analyst Decision
- RCEL Buy
- CNTX Strong Buy
- Analyst Count
- RCEL 5
- CNTX 7
- Target Price
- RCEL $11.75
- CNTX $5.40
- AVG Volume (30 Days)
- RCEL 196.9K
- CNTX 298.2K
- Earning Date
- RCEL 11-06-2025
- CNTX 11-05-2025
- Dividend Yield
- RCEL N/A
- CNTX N/A
- EPS Growth
- RCEL N/A
- CNTX N/A
- EPS
- RCEL N/A
- CNTX N/A
- Revenue
- RCEL $72,401,000.00
- CNTX N/A
- Revenue This Year
- RCEL $19.96
- CNTX N/A
- Revenue Next Year
- RCEL $33.43
- CNTX N/A
- P/E Ratio
- RCEL N/A
- CNTX N/A
- Revenue Growth
- RCEL 20.59
- CNTX N/A
- 52 Week Low
- RCEL $3.35
- CNTX $0.49
- 52 Week High
- RCEL $14.16
- CNTX $1.65
- Technical
- Relative Strength Index (RSI)
- RCEL 47.62
- CNTX 49.75
- Support Level
- RCEL $3.64
- CNTX $1.00
- Resistance Level
- RCEL $4.09
- CNTX $1.16
- Average True Range (ATR)
- RCEL 0.25
- CNTX 0.10
- MACD
- RCEL 0.06
- CNTX -0.00
- Stochastic Oscillator
- RCEL 76.87
- CNTX 54.92
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.